In today's ACT Brief, we examine what patient-site relationships need most at DPHARM, how platform-based AI scales across ...
As the life sciences industry continues to evolve, the ability to effectively manage and leverage preclinical CRO ...
In today's ACT Brief, we examine FDA's expedited pathway for first-in-human trials, why operating model design matters more ...
Benchmarking data showed sourcing approach did not reliably predict timeline, quality, or execution performance across 133 ...
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has ...
In a video interview prior to the 2026 DPHARM conference, Andrea Valente, CEO of uMotif, discussed the patient-site relationship, the role of technology in clinical trial delivery ...
In today's ACT Brief, we examine what genuine patient voice requires beyond buzzwords, why AI's next bottleneck is system ...
A platform-based approach connects AI across workflows, data and governance, helping life sciences organizations move from isolated wins to real scale. AI adoption is moving quickly in life sciences, ...
Why clinical development’s next AI bottleneck is not the model, but the system around it. “An AI-enabled workflow should identify the downstream implications of a change, propose aligned updates, ...
Why clinical development’s next AI bottleneck is not the model, but the system around it.
The clinical research industry talks about patient-centeredness constantly but embeds it too late, too narrowly, and without clear ownership, and the cost shows up in enrollment failures, protocol ...
Julie Ross is CEO of StuffThatWorks, a patient-reported real-world data platform spanning chronic conditions. The author's company affiliation is disclosed in the interest of transparency; this ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results